Faten Abo-Aziza
Dr. Faten A.M Abo-Aziza, is Associate professor and manager of the central lab of Veterinary Research Institute, National Research Centre, Egypt. Dr. Faten has many scientific papers and projects either presented or published. She has experiences and interests in many areas of advanced medicine including Stem Cell therapy.
Dr. Faten has been published more than 32 articles including stem cells research in international journals and she supervises many scientific theses in different faculties and universities including Faculty of Veterinary Medicine, Pharmacy and Science at Cairo University, Menia University and Ain Shams University. Dr. Faten succeed to provide unique drug delivery system of integrating stem sells, nanoparticles, and specific antibodies in the pursuit of developing novel alternative therapies. She reviewed many articles submitted to international specific journals and she is served as editorial member of Universe Publishing Group journal.
Dr. Faten has served as a member of various medical and scientific societies and acted on a number of institutional committees. She has been attenuated in national and international conferences and workshops in many countries including Egypt, United States, France, Spain, India and China.
She is working in many scientific projects either as the principal investigator or a member. The most recent one as principal investigator titled “Mesenchymal stem cell-nanoparticles based drug delivery system for hepatorenal endotoxicosis and aflatoxicosis rat models”.
Dr. Faten holds a BSc. in Veterinary Medicine, Cairo University, 2001.
She obtained Master’s degree in Physiology from Cairo University and finished her Ph.D. in Physiology at 2012.
She completed a Post doctor fellowship on Stem cell research in the Department of Molecular Biology and Oral Anatomy at Kyushu University, Graduate School of Dental Science, Japan, 2015. She completed her post doctor fellowship on Stem cell research in Pharmaceutical Health Science Centre, Texas Tech University, USA, 2022.
Dr. Faten has been published more than 32 articles including stem cells research in international journals and she supervises many scientific theses in different faculties and universities including Faculty of Veterinary Medicine, Pharmacy and Science at Cairo University, Menia University and Ain Shams University. Dr. Faten succeed to provide unique drug delivery system of integrating stem sells, nanoparticles, and specific antibodies in the pursuit of developing novel alternative therapies. She reviewed many articles submitted to international specific journals and she is served as editorial member of Universe Publishing Group journal.
Dr. Faten has served as a member of various medical and scientific societies and acted on a number of institutional committees. She has been attenuated in national and international conferences and workshops in many countries including Egypt, United States, France, Spain, India and China.
She is working in many scientific projects either as the principal investigator or a member. The most recent one as principal investigator titled “Mesenchymal stem cell-nanoparticles based drug delivery system for hepatorenal endotoxicosis and aflatoxicosis rat models”.
Dr. Faten holds a BSc. in Veterinary Medicine, Cairo University, 2001.
She obtained Master’s degree in Physiology from Cairo University and finished her Ph.D. in Physiology at 2012.
She completed a Post doctor fellowship on Stem cell research in the Department of Molecular Biology and Oral Anatomy at Kyushu University, Graduate School of Dental Science, Japan, 2015. She completed her post doctor fellowship on Stem cell research in Pharmaceutical Health Science Centre, Texas Tech University, USA, 2022.
less
Uploads
Papers by Faten Abo-Aziza
Materials and Methods: BM-MSCs viability, phenotypes, and proliferation were evaluated. Hepatogenic differentiation, albumin, and a-fetoprotein gene expression were assessed. AF acute hepatitis was induced in rats using AFB1 supplementation. The transplantation of BM-MSCs or their HDCs was done either by IV or IH route. Hepatic ultrasound was performed after 3-weeks of therapy. Cytokines profile (tumor necrosis factor-α [TNF-α], interleukin [IL]-4, and IL-10) was assessed. Hepatic bio-indices, serum, and hepatic antioxidant activity were evaluated, besides examining liver histological sections.
Results: Acute AFB1 showed a significant increase in TNF-α (p<0.01), liver enzyme activities (p<0.05), as well as decrease in IL-4, IL-10, and antioxidant enzyme activities (p<0.05). Cytokines profile was ameliorated in groups treated with IV and IH BM-MCs, showed a negative correlation between IL-4 and TNF-α (p<0.05), and a positive correlation between IL-10 upregulation and TNF-α (p<0.01). In IV HDCs treated group, positive correlations between IL-4 and IL-10 downregulation and TNF-α were observed. However, in IH HDCs group, a significant positive correlation between IL-4 and IL-10 upregulation and TNF-α, were recorded (p<0.05). In addition, IV BM-MSCs and IH HDCs treatments significantly increased antioxidant enzymes activity (p<0.05). IV and IH BM-MSCs significantly ameliorated liver transaminase levels, whereas IH HDCs significantly ameliorated alanine aminotransferase activity and nitric oxide concentration (p<0.05).
Conclusion: The administration routes of BM-MSCs did not demonstrate any significant difference; however, the IH route of HDCs showed significant amelioration from the IV route. On the other hand, it showed noticeable anti-inflammatory and immunomodulatory improvements in aflatoxicosis rats. Therefore, it can be concluded that acute hepatitis can be treated by a noninvasive IV route without the expense of hepatogenic differentiation. Further research using clinical trials that address several problems regarding engraftment and potentiation are needed to determine the optimal manipulation strategy as well as to achieve better long-term effects.
Materials and Methods: BM-MSCs viability, phenotypes, and proliferation were evaluated. Hepatogenic differentiation, albumin, and a-fetoprotein gene expression were assessed. AF acute hepatitis was induced in rats using AFB1 supplementation. The transplantation of BM-MSCs or their HDCs was done either by IV or IH route. Hepatic ultrasound was performed after 3-weeks of therapy. Cytokines profile (tumor necrosis factor-α [TNF-α], interleukin [IL]-4, and IL-10) was assessed. Hepatic bio-indices, serum, and hepatic antioxidant activity were evaluated, besides examining liver histological sections.
Results: Acute AFB1 showed a significant increase in TNF-α (p<0.01), liver enzyme activities (p<0.05), as well as decrease in IL-4, IL-10, and antioxidant enzyme activities (p<0.05). Cytokines profile was ameliorated in groups treated with IV and IH BM-MCs, showed a negative correlation between IL-4 and TNF-α (p<0.05), and a positive correlation between IL-10 upregulation and TNF-α (p<0.01). In IV HDCs treated group, positive correlations between IL-4 and IL-10 downregulation and TNF-α were observed. However, in IH HDCs group, a significant positive correlation between IL-4 and IL-10 upregulation and TNF-α, were recorded (p<0.05). In addition, IV BM-MSCs and IH HDCs treatments significantly increased antioxidant enzymes activity (p<0.05). IV and IH BM-MSCs significantly ameliorated liver transaminase levels, whereas IH HDCs significantly ameliorated alanine aminotransferase activity and nitric oxide concentration (p<0.05).
Conclusion: The administration routes of BM-MSCs did not demonstrate any significant difference; however, the IH route of HDCs showed significant amelioration from the IV route. On the other hand, it showed noticeable anti-inflammatory and immunomodulatory improvements in aflatoxicosis rats. Therefore, it can be concluded that acute hepatitis can be treated by a noninvasive IV route without the expense of hepatogenic differentiation. Further research using clinical trials that address several problems regarding engraftment and potentiation are needed to determine the optimal manipulation strategy as well as to achieve better long-term effects.